A combination of antitumor approaches acting on dierent death pathways seems ideal for increasing therapeutic responses, especially when de®ned resistance mechanisms interfere with individual cellular processes. Apoptosis pathways triggered by ionizing radiation (XRT) and the death ligand TRAIL were analysed in Jurkat lymphoma cells. Both induced the activation of caspase-8, caspase-3, BID and mitochondrial potential loss. TRAIL induced apoptosis required caspase-8, whereas it was not essential for radiation induced apoptosis. The inhibition of mitochondrial damage by Bcl-2 abrogated XRT induced apoptosis and caspase activation, but only marginally attenuated TRAIL induced cell death. The combined treatment with TRAIL and XRT exerted additive apoptotic eects in control cells, whereas highly synergistic eects occurred in cells overexpressing Bcl-2. In addition, a strong eect of TRAIL on radiation induced clonogenic cell death was found. In conclusion, TRAIL seems to be of high potential value for a combination with ionizing radiation in tumor therapy. Oncogene (2001) 20, 2190 ± 2196.
Keywords: TRAIL; radiation; caspase-8; Bcl-2; apoptosis Induction of apoptosis in tumor cells is an important goal for medical and radiooncological tumor treatment strategies. However, disordered gene expression in tumor cells leads to the induction of apoptosis resistance rendering tumor cells insensitive to various treatments. Dierent mechanisms have been elucidated which participate in apoptosis resistance. Up to now many key molecules shown to be relevant for apoptosis resistance in vivo belong to the Bcl-2 family or aect the function of the p53 system. Especially in human lymphomas alterations of the Bcl-2 system have been found to be critical for apoptosis resistance, treatment responses and survival of patients (Hill et al., 1996) .
The execution of apoptosis is essentially controlled by caspases, a family of intracellular cysteine proteases that are synthesized as inactive precursors and need to be activated by proteolytic processing. The activation of caspases can be mediated via two principal pathways. One involves the ligation of death receptors, such as CD95, DR3 or the TRAIL receptors. Trimerization of the CD95 receptor by its ligand CD95L recruits the FADD adapter molecule to the receptor complex which in turn triggers the autoproteolytic activation of caspase-8 (Chinnaiyan et al., 1995; Muzio et al., 1996) . Active caspase-8 leads to the proteolytic activation of downstream caspases including caspase-3 which degrades a broad range of cellular proteins, thereby inducing the apoptotic phenotype. Thus, caspase-8 acts as key player for CD95 induced apoptosis (Juo et al., 1998; Varfolomeev et al., 1998) . However, this simple signaling cascade is complicated by the presence of a mitochondrial ampli®cation loop (Scadi et al., 1998; Luo et al., 1998) . In this scenario, caspase-8 induces the proteolytic activation of the proapoptotic Bcl-2 member BID which mediates the release of cytochrome c from mitochondria (Luo et al., 1998) . Cytochrome c forms a complex with dATP and APAF-1, thereby inducing the activation of caspase-9 and downstream eector caspases. Thus, in cases of low initial caspase-8 activation the direct eect of caspase-8 on caspase-3 is ampli®ed by the mitochondrial pathway, which can be inhibited by anti-apoptotic members of the Bcl-2 family (Luo et al., 1998) . However, since the mitochondrial pathway is activated in parallel to the direct caspase pathway, prevention of cytochrome c release does not completely abrogate CD95 induced cell death (Scadi et al., 1998) .
In contrast to death receptor induced apoptosis, the processes required for DNA damage mediated apoptosis are less precisely understood. A widely accepted mechanism for the generation of initial apoptotic signals in response to DNA damage requires an intact p53 system (Lowe et al., 1993) . P53 induced apoptosis is executed via the mitochondrial pathway requiring APAF-1 and caspase-9 (Soengas et al., 1999) . The transcriptional activation of Bax expression was shown to be a key event for p53 mediated cell death (Miyashita and Reed, 1995) , which mediates the release of cytochrome c from mitochondria in a Bcl-2 controlled manner (Rosse et al., 1998) .
We have recently shown that ionizing radiation induces the activation of caspase-8 similar to CD95 stimulation. However, although caspase-8 is activated in response to ionizing radiation, CD95 pathways do not contribute to radiation induced apoptosis. Thus, CD95 and radiation induced apoptosis pathways are distinct despite using an overlapping set of molecules (Belka et al., 2000) .
In the present study, we speculated that a combination of death receptor stimulation and radiation therapy might be useful to increase treatment responses. Unfortunately, activation of the CD95 system by CD95L is associated with signi®cant systemic toxicity. In contrast, TRAIL (APO2L), another member of the death ligand family, does not exert any toxicity in several in vitro systems as well as in murine and primate models (Ashkenazi et al., 1999; Walczak et al., 1999) . Remarkably, it has been reported that the majority of tumor cell lines tested are sensitive to TRAIL-induced apoptosis, while most nontransformed cell types are TRAIL resistant (Ashkenazi et al., 1999; Walczak et al., 1999) . Therefore, TRAIL seems to be a prime candidate for a combination with ionizing radiation in order to increase antitumor responses.
Con¯icting results have been presented on the implication of TRAIL signaling pathways for DNA damage mediated apoptosis. Whereas Walczak and colleagues provided evidence that the pathways induced by the cytostatic agent etoposide are distinct from those induced by TRAIL, others suggested that TRAIL receptor activation is directly involved in etoposide and radiation mediated cell death in some cell systems (Gibson et al., 2000, Gong and Almason 2000) . Thus, we analysed how far death pathways induced by ionizing radiation and by TRAIL are distinct and whether a combination of both stimuli can overcome apoptosis resistance of tumor cells.
In a ®rst set of experiments we determined the time course and dose response relationships of radiation and recombinant human TRAIL (rHs TRAIL) induced cell death in Jurkat T-lymphoma cells. As shown in Figure  1a , both stimuli induced a dose and time dependent activation of apoptosis. Irradiation with 10 Gy induced apoptosis in *70% of the cells after 48 h. Similarly, 100 ng/ml TRAIL induced apoptosis in approximately 80% of the Jurkat cells. In parallel, we tested the in¯uence of Bcl-2 overexpression on radiation and TRAIL induced apoptosis. Apoptosis induction by ionizing radiation was markedly reduced for all radiation doses tested ( Figure 1a ). In contrast, the in¯uence of Bcl-2 on TRAIL induced apoptosis was highly dependent on the dose of TRAIL used. The level of apoptosis induced by high doses of TRAIL (100 ng/ml) was comparable to that induced in vector control cells, although overexpression of Bcl-2 reduced the kinetic of apoptosis induction ( Figure 1a ). However, apoptosis induction by lower doses of TRAIL was signi®cantly weaker in cells overexpressing Bcl-2 ( Figure 1a) .
Next to the determination of apoptosis, the activation of caspase-8 and caspase-3 was tested by Western blotting (Figure 1b) . Whereas Bcl-2 overexpression abrogated the proteolytic activation of caspase-8 and caspase-3 almost completely in response to radiation, the eect of Bcl-2 on TRAIL induced caspase activation was more complex. After stimulation with 100 ng/ml TRAIL the maximal activation of caspase-8 occurred delayed and the consumption of pro-caspase-8 was reduced in Bcl-2 overexpressing cells. Using an antibody against the active form of caspase-3, also slight dierences in caspase-3 activation were detectable. After stimulation with 10 or 25 ng/ml TRAIL the reduced activation of caspase-8 was paralleled by an attenuated activation of caspase-3.
Caspase-8 mediated cleavage of BID was recently shown to be the key step for mitochondrial damage exerted by CD95 receptor activation. Similarly, TRAIL and radiation induced proteolysis of BID into the mature p15 BID fragment (Figure 2a ). Although both treatments induced BID cleavage, TRAIL treatment was much more ecient, indicated by the fact that the proform of BID was almost completely processed into the active fragment and thus was no longer detectable 6 h after TRAIL stimulation. Bcl-2 overexpression blocked BID activation in response to ionizing radiation, whereas BID activation by high doses of TRAIL was only attenuated (Figure 2a) .
In a next set of experiments we tested how far Bcl-2 overexpression interfered with TRAIL or radiation induced breakdown of the mitochondrial potential Dc m . Both treatments induced a left shift of the TMRE¯uorescence indicating mitochondrial depolarization (Figure 2b ). The breakdown of Dc m by ionizing radiation was almost completely abrogated by Bcl-2. In contrast, overexpression of Bcl-2 interfered with the breakdown of the mitochondrial potential only in cells stimulated with lower doses of TRAIL (10 or 25 ng/ ml). No signi®cant in¯uence of Bcl-2 on the breakdown of Dc m was detectable after 24 h of stimulation with 100 ng/ml TRAIL (Figure 2b ).
Several observations showed that death receptors including CD95, TNF-RI and DR3 require caspase-8 for induction of apoptosis. Since it was shown that TRAIL induced apoptosis requires FADD (Schneider et al., 1997) , it seemed likely that TRAIL also requires caspase-8. Indeed, TRAIL induced apoptosis was strongly reduced in Jurkat cells lacking caspase-8 (77.0+10.1% apoptosis after 100 ng TRAIL/ml in caspase-8 expressing Jurkat A3 cells versus 21.6+12.3% apoptosis in caspase-8 de®cient cells after 24 h). This ®nding is in line with a recent report (Sprick et al., 2000) showing that caspase-8 is essential for TRAIL induced cell death. In contrast, ionizing radiation induced apoptosis did not dier signi®cantly between both cell lines (data not shown and Belka et al., 2000) .
To further determine the relative position of caspase activation and mitochondrial damage during TRAIL or radiation induced apoptosis, cells were treated with the broad spectrum caspase inhibitor zVAD (30 mM) 1 h prior to apoptosis induction. The mitochondrial potential was analysed 48 h later. Whereas TRAIL mediated breakdown of the mitochondrial potential (cells with Dc m low) was strongly inhibited by zVAD (25 ng/ml TRAIL: 66.3+4.04% Dc m low; 25 ng/ml TRAIL plus zVAD: 14.5+1.8% Dc m low; 100 ng/ml TRAIL: 87.3+5.5% Dc m low; 100 ng/ml TRAIL plus zVAD: 18.1+3.3% Dc m low), caspase inhibition did not prevent the breakdown of the mitochondrial potential in response to ionizing radiation (5 Gy: 38.0+4.0% Dc m low; 5 Gy plus zVAD: 35.3+9.0% Dc m low; 10 Gy: 64.3+3.1% Dc m low; 10 Gy plus zVAD: 59.0+7.8% Dc m low).
At this point the data indicated that TRAIL acts mainly via direct caspase-8 activation and does not strictly depend on Bcl-2 inhibitable pathways, whereas radiation induced apoptosis and caspase activation can be controlled by Bcl-2. Since it was shown that in some cells a Bcl-2 inhibitable mitochondrial ampli®cation loop initiated by BID cleavage is required for a rapid and strong apoptotic response following CD95 stimulation (Scadi et al., 1998; Yin et al., 1999) , our data suggest that, analogously, BID cleavage is involved in apoptosis induction in response to lower TRAIL doses. Thus, radiation induced apoptosis almost completely relies on mitochondrial pathways with caspase activation occurring secondarily to mitochondrial damage. In contrast, TRAIL induced apoptosis primarily relies on direct caspase activation, and the mitochondrial proapoptotic machinery merely constitutes an ampli®ca- Apoptosis induction in response to 10, 25 and 100 ng/ml TRAIL was determined by FACS analysis after 12, 24 and 48 h. Apoptosis was triggered using FLAG tagged recombinant human TRAIL (Alexis, GruÈ nberg, Germany) and a monoclonal anti-FLAG antibody to induce ligand trimerization. The overexpression of Bcl-2 altered the initial slope of 100 ng/ml TRAIL induced apoptosis, with no signi®cant dierences in apoptosis induction after 24 and 48 h. In contrast, Bcl-2 attenuated apoptosis induction in response to lower doses of TRAIL. The anti-FLAG antibody alone did not exert any eect. Right panel: Radiation induced apoptosis was determined 24 and 48 h after irradiation with 2, 5 and 10 Gy. Bcl-2 overexpression almost completely abrogated the induction of apoptosis. (b) The proteolytic activation of caspase-8 and caspase-3 was detected by immunoblotting (Belka et al., 2000) at the indicated time points after stimulation with 10, 25 and 100 ng TRAIL/ml. Overexpression of Bcl-2 only slightly reduced the activation in response to 100 ng TRAIL/ml. In contrast, caspase activation was reduced in response to lower doses of TRAIL (left panel). Similarly, proteolytic activation of caspase-8 and caspase-3 was analysed 12, 14, 16, 18 h after irradiation with 10 Gy. The overexpression of Bcl-2 strongly attenuated the activation of caspases (right panel)
Combined effects of TRAIL and ionizing radiation C Belka et al tion loop for ecient apoptosis. Therefore, we hypothesized that a combination of both treatments might prove ideal to increase apoptosis induction. Jurkat vector control cells were treated with combinations of 1, 5, 10, 25 ng/ml TRAIL together with 2, 5, and 10 Gy. TRAIL was added 1 h prior to irradiation, and apoptosis was determined 24 and 48 h later. As shown in Figure 3a , the combination of various amounts of TRAIL with 5 or 10 Gy irradiation induced signi®cantly more apoptosis than either treatment alone. Since Bcl-2 overexpression is a major negative predictive factor for the clinical outcome in leukemia and lymphoma, we tested the eect of a combination of TRAIL and ionizing radiation in Jurkat cells overexpressing Bcl-2. As shown above, those cells were highly resistant to radiation but only partially to TRAIL induced apoptosis. Cells were therefore incubated with dierent concentrations of TRAIL 1 hour prior to irradiation with 2, 5, or 10 Gy.
As shown in Figure 3b , the combination of TRAIL with irradiation strongly induced apoptosis in cells overexpressing Bcl-2. To determine in how far the interaction was additive, less than additive or synergistic, a detailed isobolographic analysis was performed. The combined treatment induced additive changes in cells not expressing Bcl-2, whereas remarkable synergistic eects were observed in cells overexpressing Bcl-2 (Figure 4a ). Of special importance was that these synergistic eects were obtained with combinations of low doses of TRAIL and the standard treatment fractionation dose of 2 Gy.
In order to gain insights into the mechanism underlying the observed synergistic eect, we speculated that irradiation in the apoptosis resistant cells might strongly sensitize those cells to the eects of TRAIL. To test this, irradiated Bcl-2 overexpressing cells were treated with TRAIL 12 h after irradiation. The mitochondrial transmembrane potential (Dc m ) was analysed using the Dc m speci®c dye TMRE (Molecular Probes, Mobitech, GoÈ ttingen, Germany) as described previously (Belka et al., 2000) . Dc m was determined 24 h after stimulation with the indicated amounts of TRAIL and 48 h after irradiation with 2, 5 or 10 Gy. The organic cyanide CCCP (10 mM, 30 min) served as a positive control. Bcl-2 strongly reduced the breakdown of Dc m in response to all doses of ionizing radiation, whereas Bcl-2 only partially protected against TRAIL mediated mitochondrial damage Caspase-8 activation, as a biochemical marker for TRAIL sensitivity, was tested in response to irradiation alone and TRAIL over the following 4 h. As shown in Figure 4b , irradiation alone did not induce any detectable caspase-8 activity even after 18 h. However, caspase-8 activation in response to TRAIL was strongly increased in pre-irradiated cells, indicating that ionizing radiation sensitizes Bcl-2 overexpressing cells to the eects of TRAIL. The increased sensitivity could be mediated at the level of TRAIL receptors. Indeed, it has been observed that DNA damage can increase the expression of TRAIL receptor DR5 (Sheikh et al., 1998) . An alternative explanation is the possibility that pre-irradiation may in¯uence the level of Bcl-2. In this regard it was shown that apoptotic stimuli can convert anti-apoptotic Bcl-2 into a pro-apoptotic Bcl-2 fragment (Kirsch et al., 1999) . To test either hypothesis, the in¯uence of the preirradiation on the Bcl-2 and TRAIL receptor levels was investigated. As shown by Western blotting (Figure   4c ), radiation did not signi®cantly reduce the levels of Bcl-2. Furthermore, no characteristic cleavage product indicating the conversion of Bcl-2 into a pro-apoptotic fragment was detectable. In contrast, both FACS and Western blot analysis showed that radiation induced an increased surface expression of DR5 in vector control and Bcl-2 overexpressing Jurkat cells (Figure 4d ).
Taken together, these ®ndings suggest that the combined eect of TRAIL and irradiation is rather based on the receptor level than on alterations in Bcl-2 expression. This interpretation is also supported by data derived from the Bax negative breast cancer line R30C (Bargou et al., 1995) . In this context the lack of Bax rather than overexpression of Bcl-2 resulted in an abrogation of radiation induced cell death (10 Gy, 24 h: 4.5+5.1%). Nevertheless, TRAIL still induced apoptosis in these cells, again supporting the model of distinct signaling pathways (100 ng/ml TRAIL, 24 h: 39.3+7.9%). Similar to the situation with Bcl-2 overexpressing Jurkat cells, the combination of TRAIL and radiation exerted strong synergistic eects (10 Gy plus 100 ng/ml TRAIL, 24 h: 68.6+16.1%).
Since alterations of the apoptotic response are not necessarily paralleled by an increased eradication of clonogenic tumors cells (Aldridge et al., 1995) , the combined eect of TRAIL and radiation on the radiation dose required to abrogate clonogenic cell growth in 50% of the wells (TCD50) was tested as described (Green et al., 1991) , and a detailed isobologram analysis (Steel and Peckham, 1979; Greco et al., 1995) was performed. After seeding 250 cells/ml of the Bcl-2 overexpressing Jurkat clone in each well, the TCD50 values for the dierent treatments were as follows: radiation alone: 4.4 Gy, 95% con®dence interval 4.0 ± 4.8 Gy; radiation plus 25 ng/ml TRAIL: 1.2 Gy, 95% con®dence interval 0.8 ± 1.8 Gy. After (Steel and Peckham, 1979) was performed for the observed combined eects of TRAIL and radiation in vector transfected cells (upper panel) and Bcl-2 transfected cells (lower panel). For preparation of the isobolograms dose response curves for either radiation or TRAIL induced apoptosis were created. The derived linear functions of either dose response curve were used to calculate the range of additivity for an observed combined eect. The shaded area between the lines represents values of additivity. Data points of a combined treatment which fall to the left of this area indicate synergy. The dots indicate the real dose combination used to achieve the observed eect on apoptosis induction. The observed combined eect for the individual isobologram is indicated (per cent apoptosis induction 48 h after stimulation). (b) Bcl-2 overexpressing cells were pre-irradiated with 10 Gy and treated with 25 ng/ml TRAIL. Caspase-8 activation was determined by Western blotting 18 h after irradiation alone (left panel), 1, 2, and 4 h after TRAIL treatment in non-irradiated cells (middle panel), and 1, 2, and 4 h after TRAIL addition in cells 12 h after pre-irradiation with 10 Gy (right panel). (c) Eect of ionizing radiation on the level of Bcl-2: After Western blotting with a Bcl-2 speci®c antibody (Santa Cruz Biotechnology, Heidelberg, Germany) no changes in Bcl-2 levels after irradiation with 10 Gy were detectable. Furthermore, no pro-apoptotic cleavage of Bcl-2 was observed. (d) Ionizing radiation increases the surface expression of TRAIL receptor DR5. Jurkat vector control and Bcl-2 overexpressing cells known to express only the DR5 receptor were irradiated with 10 Gy. Twelve hours after irradiation cells were incubated with 250 ng/ml FLAG tagged TRAIL (Alexis) for 15 min at 48C. TRAIL binding was detected bȳ ow cytometry using a monoclonal antibody against the FLAG tag (1 mg/ml TRAIL Enhancer, Alexis) and FITC labeled antimouse IgG (Dianova, Hamburg, Germany). An isotype-matched irrelevant antibody served as a control. The radiation induced increase in auto-¯uorescence was compensated using the Igor Pro software package. Ionizing radiation induced a signi®cant increase in TRAIL binding in both vector control and Bcl-2 overexpressing cells. In parallel, Western blotting using a polyclonal DR5 antiserum (Cayman Chemicals, Ann Arbor, MI, USA) revealed a strong increase in DR5 protein levels 12 and 24 h after irradiation with 10 Gy seeding a higher number of Bcl-2 overexpressing cells (2500 cells/ml) in each well the TCD 50 values were for radiation: 7 Gy, 95% con®dence interval 6.5 ± 7.6 Gy; and for radiation plus 25 ng/ml TRAIL: 4.5 Gy, 95% con®dence interval 4.1 ± 4.9 Gy. Thus, the addition of 25 ng/ml TRAIL reduced the isoeective radiation dose by roughly 3 Gy.
Taken together, a combination of TRAIL and ionizing radiation was highly synergistic and potentiated the ecacy of both apoptosis induction and eradication of clonogenic cells. Importantly, ionizing radiation increased apoptosis and clonogenic cell kill in cells overexpressing the antiapoptotic Bcl-2 protein, which is frequently overexpressed in a multitude of human tumors. In contrast to CD95L, TRAIL has no apparent toxicity in mice or primates (Walczak et al., 1999; Ashkenazi et al., 1999) . Only a few recent reports suggested that at least some preparations of TRAIL are able to trigger apoptosis in normal human liver and brain cells (Jo et al., 2000; Nitsch et al., 2000) . Since TRAIL was shown to be active in various transformed cell types such as colorectal, glioblastoma, breast lung cancer and melanoma cells, administration of TRAIL either alone or in conjunction with ionizing radiation may be an eective and promising strategy to kill tumor cells.
